In conclusion, no significant difference was detected in serum IGF-1, GH, IGFBP-2 or IGFBP-3 levels between the MS group and healthy control, except for IGFBP-1 which was higher in MS cases than controls. This evidence concerns the gene GH1 and myeloid sarcoma.